These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1015 related items for PubMed ID: 25530271

  • 1. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V.
    Int J Cancer; 2015 Aug 01; 137(3):678-85. PubMed ID: 25530271
    [Abstract] [Full Text] [Related]

  • 2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A.
    Lancet Oncol; 2016 Dec 01; 17(12):1697-1708. PubMed ID: 27776843
    [Abstract] [Full Text] [Related]

  • 3. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD.
    BMC Cancer; 2020 Sep 15; 20(1):886. PubMed ID: 32933498
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
    Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, Graeven U, Schulte N, Merx K, Pohl M, Held S, Keller R, Tannapfel A, Al-Batran SE.
    Int J Cancer; 2021 Sep 15; 149(6):1322-1331. PubMed ID: 34019698
    [Abstract] [Full Text] [Related]

  • 5. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
    Molina R, Lamarca A, Martínez-Amores B, Gutiérrez A, Blázquez A, López A, Granell J, Álvarez-Mon M.
    Eur J Surg Oncol; 2013 Aug 15; 39(8):814-22. PubMed ID: 23755989
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD.
    J Clin Oncol; 2010 May 01; 28(13):2213-9. PubMed ID: 20351330
    [Abstract] [Full Text] [Related]

  • 8. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC, Ubink I, van der Horst S, Boonstra JJ, Voest EE, Ruurda JP, Borel Rinkes IH, Wiezer MJ, Schipper ME, Siersema PD, Los M, Lolkema MP, van Hillegersberg R.
    Ann Surg Oncol; 2015 May 01; 22(5):1555-63. PubMed ID: 25564156
    [Abstract] [Full Text] [Related]

  • 9. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
    Ozdemir N, Abali H, Vural M, Yalcin S, Oksuzoglu B, Civelek B, Oguz D, Bostanci B, Yalcin B, Zengin N.
    Cancer Chemother Pharmacol; 2014 Dec 01; 74(6):1139-47. PubMed ID: 25234436
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study.
    Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan XB, Lu CM, Wang JB, Deng WY, Ma YJ, Bie LY, Wang MY, Li J, Xia QX, Wei C, Luo SX.
    Int J Surg; 2024 Apr 01; 110(4):2071-2084. PubMed ID: 38320099
    [Abstract] [Full Text] [Related]

  • 11. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T, Bronsert P, Schäfer M, Kulemann B, Marjanovic G, Sick O, Hopt UT, Zirlik K, Makowiec F, Hoeppner J.
    Eur J Surg Oncol; 2015 Oct 01; 41(10):1300-7. PubMed ID: 26253194
    [Abstract] [Full Text] [Related]

  • 12. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M, Lequesne J, Leconte A, Corbinais S, Parzy A, Guilloit JM, Varatharajah S, Brachet PE, Dorbeau M, Vaur D, Weiswald LB, Poulain L, Le Gallic C, Castera-Tellier M, Galais MP, Clarisse B.
    BMC Cancer; 2022 May 12; 22(1):537. PubMed ID: 35549674
    [Abstract] [Full Text] [Related]

  • 13. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F.
    BMC Cancer; 2019 May 24; 19(1):494. PubMed ID: 31126258
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD.
    JAMA Oncol; 2017 Sep 01; 3(9):1237-1244. PubMed ID: 28448662
    [Abstract] [Full Text] [Related]

  • 16. A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
    Larsen AC, Holländer C, Duval L, Schønnemann K, Achiam M, Pfeiffer P, Yilmaz MK, Thorlacius-Ussing O, Bæksgaard L, Ladekarl M.
    Ann Surg Oncol; 2015 May 01; 22(5):1540-7. PubMed ID: 25348777
    [Abstract] [Full Text] [Related]

  • 17. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
    Götze TO, Piso P, Lorenzen S, Bankstahl US, Pauligk C, Elshafei M, Amato G, Reim D, Bechstein WO, Königsrainer A, Mönig SP, Rau B, Schwarzbach M, Al-Batran SE.
    BMC Cancer; 2021 Oct 29; 21(1):1158. PubMed ID: 34715810
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB.
    Oncologist; 2019 Aug 29; 24(8):1039-e642. PubMed ID: 31138725
    [No Abstract] [Full Text] [Related]

  • 19. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD, Bayraktar S, Hosein P, Chen E, Koniaris LG, Rocha-Lima CM, Montero AJ.
    Med Oncol; 2012 Sep 29; 29(3):1707-10. PubMed ID: 22033912
    [Abstract] [Full Text] [Related]

  • 20. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC.
    J Clin Oncol; 2014 Sep 20; 32(27):2983-90. PubMed ID: 25071104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.